company background image
BIM

bioMérieux ENXTPA:BIM Stock Report

Last Price

€88.52

Market Cap

€10.5b

7D

-1.9%

1Y

-6.3%

Updated

15 May, 2022

Data

Company Financials +
BIM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends3/6

BIM Stock Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

bioMérieux Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bioMérieux
Historical stock prices
Current Share Price€88.52
52 Week High€133.20
52 Week Low€80.70
Beta-0.11
1 Month Change-6.47%
3 Month Change-12.40%
1 Year Change-6.27%
3 Year Change20.11%
5 Year Change45.91%
Change since IPO785.20%

Recent News & Updates

May 11
Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Apr 23
bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux S.A.'s ( EPA:BIM ) dividend will be increasing to €0.85 on 8th of June. Despite this raise, the dividend...

Shareholder Returns

BIMFR Medical EquipmentFR Market
7D-1.9%-1.8%1.6%
1Y-6.3%-8.5%-4.2%

Return vs Industry: BIM exceeded the French Medical Equipment industry which returned -8.5% over the past year.

Return vs Market: BIM underperformed the French Market which returned -4.2% over the past year.

Price Volatility

Is BIM's price volatile compared to industry and market?
BIM volatility
BIM Average Weekly Movement6.3%
Medical Equipment Industry Average Movement6.7%
Market Average Movement6.2%
10% most volatile stocks in FR Market10.5%
10% least volatile stocks in FR Market3.6%

Stable Share Price: BIM is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BIM's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196312,232Alexandre Merieuxhttps://www.biomerieux.com

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories.

bioMérieux Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
BIM fundamental statistics
Market Cap€10.47b
Earnings (TTM)€601.10m
Revenue (TTM)€3.38b

17.4x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIM income statement (TTM)
Revenue€3.38b
Cost of Revenue€1.41b
Gross Profit€1.96b
Other Expenses€1.36b
Earnings€601.10m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 31, 2022

Earnings per share (EPS)5.08
Gross Margin58.16%
Net Profit Margin17.80%
Debt/Equity Ratio10.7%

How did BIM perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

17%

Payout Ratio

Does BIM pay a reliable dividends?

See BIM dividend history and benchmarks
When do you need to buy BIM by to receive an upcoming dividend?
bioMérieux dividend dates
Ex Dividend DateJun 06 2022
Dividend Pay DateJun 08 2022
Days until Ex dividend21 days
Days until Dividend pay date23 days

Does BIM pay a reliable dividends?

See BIM dividend history and benchmarks

Valuation

Is bioMérieux undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: BIM (€88.52) is trading below our estimate of fair value (€189.88)

Significantly Below Fair Value: BIM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BIM is poor value based on its PE Ratio (17.4x) compared to the French Medical Equipment industry average (13.4x).

PE vs Market: BIM is poor value based on its PE Ratio (17.4x) compared to the French market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: BIM's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: BIM is overvalued based on its PB Ratio (3.4x) compared to the FR Medical Equipment industry average (2.2x).


Future Growth

How is bioMérieux forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-7.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIM's earnings are forecast to decline over the next 3 years (-7.5% per year).

Earnings vs Market: BIM's earnings are forecast to decline over the next 3 years (-7.5% per year).

High Growth Earnings: BIM's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BIM's revenue (2.7% per year) is forecast to grow slower than the French market (5.7% per year).

High Growth Revenue: BIM's revenue (2.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIM's Return on Equity is forecast to be low in 3 years time (12.3%).


Past Performance

How has bioMérieux performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


22.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIM has high quality earnings.

Growing Profit Margin: BIM's current net profit margins (17.8%) are higher than last year (13%).


Past Earnings Growth Analysis

Earnings Trend: BIM's earnings have grown significantly by 22.3% per year over the past 5 years.

Accelerating Growth: BIM's earnings growth over the past year (48.6%) exceeds its 5-year average (22.3% per year).

Earnings vs Industry: BIM earnings growth over the past year (48.6%) exceeded the Medical Equipment industry 29.7%.


Return on Equity

High ROE: BIM's Return on Equity (18.8%) is considered low.


Financial Health

How is bioMérieux's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BIM's short term assets (€2.2B) exceed its short term liabilities (€955.8M).

Long Term Liabilities: BIM's short term assets (€2.2B) exceed its long term liabilities (€486.5M).


Debt to Equity History and Analysis

Debt Level: BIM has more cash than its total debt.

Reducing Debt: BIM's debt to equity ratio has reduced from 25.2% to 10.7% over the past 5 years.

Debt Coverage: BIM's debt is well covered by operating cash flow (238.5%).

Interest Coverage: BIM's interest payments on its debt are well covered by EBIT (108.2x coverage).


Balance Sheet


Dividend

What is bioMérieux current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.96%

Current Dividend Yield

Upcoming Dividend Payment

TodayMay 16 2022Ex Dividend DateJun 06 2022Dividend Pay DateJun 08 20222 days from Ex DividendBuy in the next 21 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: BIM's dividend (0.96%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.71%).

High Dividend: BIM's dividend (0.96%) is low compared to the top 25% of dividend payers in the French market (5.05%).


Stability and Growth of Payments

Stable Dividend: BIM's dividend payments have been volatile in the past 10 years.

Growing Dividend: BIM's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (16.7%), BIM's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (19.3%), BIM's dividend payments are well covered by cash flows.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Alexandre Merieux (47 yo)

4.42yrs

Tenure

€1,486,894

Compensation

Mr. Alexandre Merieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Merieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined...


CEO Compensation Analysis

Compensation vs Market: Alexandre's total compensation ($USD1.55M) is below average for companies of similar size in the French market ($USD3.61M).

Compensation vs Earnings: Alexandre's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: BIM's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: BIM's board of directors are considered experienced (9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

bioMérieux S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: bioMérieux S.A.
  • Ticker: BIM
  • Exchange: ENXTPA
  • Founded: 1963
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €10.467b
  • Shares outstanding: 118.25m
  • Website: https://www.biomerieux.com

Number of Employees


Location

  • bioMérieux S.A.
  • 376 Chemin De l’Orme
  • Marcy l'Étoile
  • Rhône-Alpes
  • 69280
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.